Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Raloxifene.

J A Kellen1

  • 1eljan@sprint.ca

Current Drug Targets
|December 6, 2001
PubMed
Summary
This summary is machine-generated.

Raloxifene, an antioestrogen, offers selective estrogen suppression with benefits for bone health and cardiovascular risk. It shows promise as a chemopreventive agent for breast cancer, with minimal side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Raloxifene: another selective estrogen modulator.

In vivo (Athens, Greece)·2002
Same author

Chemoprevention of cancer: an ongoing saga.

In vivo (Athens, Greece)·2000
Same author

Genomic effects of tamoxifen.

Anticancer research·1996
Same author

The effect of toremifene on the expression of genes in a rat mammary adenocarcinoma.

In vivo (Athens, Greece)·1996
Same author

The effect of Toremifene on the expression of some genes in human mononuclear cells.

In vivo (Athens, Greece)·1995
Same author

Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers.

International journal of cancer·1994
Same journal

Extracellular Vesicles from Mesenchymal Stem Cells Alleviate Spinal Cord Injury via the miR-486-5p/PTEN/PI3K/AKT Pathway.

Current drug targets·2026
Same journal

Improving B-cell Linear Epitope Prediction <i>via</i> Multiple Feature Fusion and an Integrated Machine Learning Algorithm.

Current drug targets·2026
Same journal

Mechanistic Insights into the Inhibition of Plasmodium falciparum DNA Gyrase A by Withanolide Derivatives through Integrated Computational Analysis.

Current drug targets·2026
Same journal

Epitranscriptomics in Breast Cancer: The Unveiled Role of RNA Modifications.

Current drug targets·2026
Same journal

Neuroinflammation in Alzheimer's Disease: New Approaches.

Current drug targets·2026
Same journal

FXYD3: A Key Regulator of Ion Homeostasis and Redox Balance in Cancer Biology.

Current drug targets·2026
See all related articles

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Endocrine manipulation is a strategy to prevent cancer initiation and promotion.
  • Antioestrogens, like Raloxifene, antagonize oestrogen effects through receptor binding and other genomic interactions.
  • Selective oestrogen modulation aims for maximal oestrogen inhibition with minimal toxicity.

Purpose of the Study:

  • To review the characteristics and therapeutic potential of Raloxifene.
  • To highlight Raloxifene's role in managing menopausal issues and preventing/treating breast cancer.
  • To discuss its selective oestrogen suppression and other beneficial effects.

Main Methods:

  • Review of existing literature on Raloxifene's pharmacological profile and clinical applications.

Related Experiment Videos

  • Analysis of Raloxifene's mechanism of action, including receptor interactions and genomic effects.
  • Evaluation of clinical trial data regarding efficacy, safety, and specific patient populations.

    • Main Results:

    • Raloxifene exhibits selective oestrogen suppression, bone demineralization reduction, and antiatherogenic effects without endometrial stimulation.
    • It is well-tolerated and has demonstrated efficacy as a breast cancer chemopreventive agent in specific populations.
    • Raloxifene does not interfere with ovulation in women with normal menstrual cycles.

    Conclusions:

    • Raloxifene is a valuable addition to therapeutic options for menopausal symptoms and breast cancer prevention/treatment.
    • Its unique profile of selective oestrogen modulation offers a favorable risk-benefit ratio.
    • Raloxifene represents a step towards advanced "designer" oestrogen modulators.